BIOCON
532523Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Meetings with Analyst(s)/Institutional Investor(s)
Biocon Ltd is a leading global biopharmaceutical company headquartered in Bengaluru, India, with a strong presence across pharmaceuticals, biologics, biosimilars, and research services. Founded in 1978, Biocon has evolved into a fully integrated biotechnology enterprise, focusing on innovative and affordable solutions for chronic diseases such as diabetes, oncology, and autoimmune conditions. The company’s diversified operations include the manufacturing and marketing of APIs, generics, biosimilars, and novel biologics, catering to over 120 countries through a combination of in-house R&D and strategic partnerships.
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Meetings with Analyst(s)/Institutional Investor(s)
Communication Regarding Remittance Of Final Dividend For The FY 2025-26
Communication regarding remittance of final dividend for the FY 2025-26
Revised Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the revised disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Mylan Inc.
Company Statement
Company Statement
Company Statement
Company Statement
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Investor Meet
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Earning call Transcript for Q1 FY27
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Voting Results and Scrutinizer''s report
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Investor Meet
Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Advertisement
Announcement under Regulation 30 (LODR)-Resignation of Statutory Auditors
Resignation of Statutory auditors of material subsidiaries of the Company.
Announcement under Regulation 30 (LODR)-Change in Directorate
Change in Directorate
Completion Of Tenure Of Statutory Auditors
Completion of tenure of Statutory Auditors
Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s
Appointment of Statutory Auditors
Announcement under Regulation 30 (LODR)-Change in Directorate
Change in Directorate
Shareholder Meeting / Postal Ballot-Outcome of AGM
Proceedings of the 48th AGM of the Company and the Chairperson''s speech.
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Audio and video recording of Q1 2027
Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation
Announcement under Regulation 30 (LODR)-Monitoring Agency Report
Monitoring Agency Report
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release
Board Meeting Outcome for Outcome Of Board Meeting
Outcome of Board Meeting
Outcome Of Board Meeting-Financial Results
Outcome of Board Meeting- Financial Results
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release
Commercial Launch Of Product
Commercial Launch of Product
Biocon Ltd
About
Biocon Ltd is a leading global biopharmaceutical company headquartered in Bengaluru, India, with a strong presence across pharmaceuticals, biologics, biosimilars, and research services. Founded in 1978, Biocon has evolved into a fully integrated biotechnology enterprise, focusing on innovative and affordable solutions for chronic diseases such as diabetes, oncology, and autoimmune conditions. The company’s diversified operations include the manufacturing and marketing of APIs, generics, biosimilars, and novel biologics, catering to over 120 countries through a combination of in-house R&D and strategic partnerships.
Business Model & Strategy
Biocon operates through multiple business verticals, including Biocon Biologics (biosimilars), Generics, Novel Biologics, and Research Services (Syngene). Revenue is generated from the sale of APIs, biosimilar drugs, contract research, and out-licensing partnerships. The company leverages its R&D capabilities, cost-effective manufacturing, and regulatory track record to supply regulated markets such as the US, Europe, and Japan as well as emerging economies.
Biocon’s growth strategy centers on expanding its biosimilars portfolio, securing regulatory approvals in new geographies, capitalizing on long-term partnerships (such as Viatris and Sandoz), and strengthening its IP and manufacturing infrastructure. The company is also investing in digital and process innovation to enhance operational efficiency and global supply reliability.
Management Overview
11 MembersMs.Kiran Mazumdar Shaw
Executive Director-Chairperson related to PromoterMr.Siddharth Mittal
Executive Director-CEO-MDMr.Ravi Rasendra Mazumdar
Non-Executive - Non Independent DirectorMr.Eric Mazumdar
Non-Executive - Non Independent DirectorMr.Bobby Kanubhai Parikh
Non-Executive - Independent DirectorMs.Naina Lal Kidwai
Non-Executive - Independent DirectorMs.Rekha Mehrotra Menon
Non-Executive - Independent DirectorMr.Nicholas Robert Haggar
Non-Executive - Independent DirectorMr.Atul Dhawan
Non-Executive - Independent DirectorMr.Mukesh Kamath
Chief Financial OfficerMs.Ekta Agarwal
Company Secretary & Compliance OfficerAwards & Recognition
5 Awards- Featured among 'Top 10 Global Biotech Employers' by Science Magazine (2023)
- ESG India Leadership Award for Sustainability (2023, 2024)
- Frost & Sullivan 'Indian Biologics Company of the Year' (2024)
- Included in the Dow Jones Sustainability Index (DJSI) - Emerging Markets (2024)
- Recipient of the 'World’s Most Ethical Companies' - Ethisphere (2024)
Market Information
Company Timeline
46+ Years of Excellence | 9 Major Milestones
Founded by Kiran Mazumdar-Shaw as an industrial enzymes company in Bengaluru.
Listed on Indian stock exchanges via IPO; one of the largest biotech IPOs in India.
Spun off contract research operations as Syngene International.
Launched first generic insulin in Japan and India.
Received USFDA approval for biosimilar Trastuzumab in the US.
Entered strategic partnership with Mylan (now Viatris) for biosimilars expansion.
Acquired Viatris’ global biosimilars business; became a leading biosimilars player.
Biocon Biologics receives multiple regulatory approvals in EU, US, and emerging markets.
Signed partnership with Sandoz for out-licensing and commercialization of biosimilars.
The Next Evolution
Contact Information
Registered Office
20th KM Hosur Road Electronic City
Tel: 080-28082808,
Fax: 080-28523423,
Email: co.secretary@biocon.com
Website: biocon.com
Corporate Actions
12| Purpose | Ex Date | Record Date | BC Start | BC End |
|---|---|---|---|---|
Final Dividend ₹0.50 per share | 03 Jul 2026 Friday | 03 Jul 2026 Friday | - | - |
Final Dividend ₹0.50 per share | 04 Jul 2025 Friday | 04 Jul 2025 Friday | - | - |
Final Dividend ₹0.50 per share | 05 Jul 2024 Friday | 05 Jul 2024 Friday | - | - |
Final Dividend ₹1.50 per share | 07 Jul 2023 Friday | 07 Jul 2023 Friday | - | - |
Final Dividend ₹0.50 per share | 30 Jun 2022 Thursday | 01 Jul 2022 Friday | - | - |
Final Dividend ₹0.50 per share | 18 Jul 2019 Thursday | 19 Jul 2019 Friday | - | - |
Bonus issue 1:1 | 12 Jun 2019 Wednesday | 13 Jun 2019 Thursday | - | - |
Final Dividend ₹1 per share | 19 Jul 2018 Thursday | 20 Jul 2018 Friday | - | - |
Final Dividend ₹1 per share | 20 Jul 2017 Thursday | - | 22 Jul 2017 Saturday | 28 Jul 2017 Friday |
Bonus issue 2:1 | 15 Jun 2017 Thursday | 17 Jun 2017 Saturday | - | - |
Interim Dividend ₹5 per share | 17 Mar 2016 Thursday | 19 Mar 2016 Saturday | - | - |
Interim Dividend ₹5 per share | 09 Apr 2015 Thursday | 10 Apr 2015 Friday | - | - |
₹65,351 Cr.
₹401
₹447 / 337
118.19
₹224.71
1.79
₹3.4
₹5.00
0.12 %
Manage Ratio
FINANCIALS
| Annual Results | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income | - | - | - | 5,659 | 6,529 | 7,360 | 8,397 | 11,550 | 15,621 | 16,470 | 17,270 | 17,638 |
| Expenses | - | - | - | 4,639 | 5,381 | 6,226 | 7,096 | 10,195 | 14,000 | 14,680 | 16,419 | 16,761 |
| Profit | - | - | - | 1,003 | 871 | 846 | 772 | 643 | 1,298 | 1,429 | 369 | 416 |
| Tax | - | - | - | 212 | 315 | 222 | 212 | 254 | 227 | 457 | 79 | 62 |
| EPS | - | - | - | 15 | 6 | 6 | 5 | 4 | 9 | 8 | 3 | 0.87 |
| Ratios | - |
Cash Flow
Consolidated Figures in Rs. Crores
| Annual Balance Sheet | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | - |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | - | - | - | 12,192 | 14,444 | 18,522 | 20,394 | 52,043 | 56,071 | 58,797 | 63,651 | - |
| Equity And Liabilities | - | - | - | 12,192 | 14,444 | 18,522 | 20,394 | 52,043 | 56,071 | 58,797 | 63,651 | - |
Shareholding Pattern
Numbers in Percentages
| Quarterly SHP Announcement Date | Mar 2016 12 Apr '16 | Mar 2017 31 Mar '17 | Mar 2018 31 Mar '18 | Mar 2019 15 Apr '19 | Mar 2020 16 Apr '20 | Mar 2021 16 Apr '21 | Mar 2022 14 Apr '22 | Mar 2023 19 Apr '23 | Mar 2024 17 Apr '24 | Mar 2025 15 Apr '25 | Mar 2026 21 Apr '26 | - |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Goverments | - | - | - | - | - | - | - | - | - | - | - | - |
| Promoter And Promoter Group | - | - | - | 60.67% | 60.67% | 60.67% | 60.64% | 60.64% | 60.64% | 60.64% | 44.91% | - |
| Non Institutions | - | - | - | 15.62% | 15.80% | 14.96% | 14.76% | 16.71% | 19.73% | 17.76% | 23.41% | - |
| FII | - | - | - | - | - | - | - | 10.20% | 5.63% | 5.66% | 7.52% | - |
| DII | - | - | - | - | - | - | - | 11.90% | 13.68% | 15.72% | 24.07% | - |
| Total | - | - | - | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | - |
Biocon Ltd
Biocon Ltd
Biocon Ltd is a leading global biopharmaceutical company headquartered in Bengaluru, India, with a strong presence across pharmaceuticals, biologics, biosimilars, and research services. Founded in 1978, Biocon has evolved into a fully integrated biotechnology enterprise, focusing on innovative and affordable solutions for chronic diseases such as diabetes, oncology, and autoimmune conditions. The company’s diversified operations include the manufacturing and marketing of APIs, generics, biosimilars, and novel biologics, catering to over 120 countries through a combination of in-house R&D and strategic partnerships.
Biocon operates through multiple business verticals, including Biocon Biologics (biosimilars), Generics, Novel Biologics, and Research Services (Syngene). Revenue is generated from the sale of APIs, biosimilar drugs, contract research, and out-licensing partnerships. The company leverages its R&D capabilities, cost-effective manufacturing, and regulatory track record to supply regulated markets such as the US, Europe, and Japan as well as emerging economies.
Biocon’s growth strategy centers on expanding its biosimilars portfolio, securing regulatory approvals in new geographies, capitalizing on long-term partnerships (such as Viatris and Sandoz), and strengthening its IP and manufacturing infrastructure. The company is also investing in digital and process innovation to enhance operational efficiency and global supply reliability.
Featured among 'Top 10 Global Biotech Employers' by Science Magazine (2023)
ESG India Leadership Award for Sustainability (2023, 2024)
Frost & Sullivan 'Indian Biologics Company of the Year' (2024)
Included in the Dow Jones Sustainability Index (DJSI) - Emerging Markets (2024)
Recipient of the 'World’s Most Ethical Companies' - Ethisphere (2024)
Founded by Kiran Mazumdar-Shaw as an industrial enzymes company in Bengaluru.
Listed on Indian stock exchanges via IPO; one of the largest biotech IPOs in India.
Spun off contract research operations as Syngene International.
Launched first generic insulin in Japan and India.
Received USFDA approval for biosimilar Trastuzumab in the US.
Entered strategic partnership with Mylan (now Viatris) for biosimilars expansion.
Acquired Viatris’ global biosimilars business; became a leading biosimilars player.
Biocon Biologics receives multiple regulatory approvals in EU, US, and emerging markets.
Signed partnership with Sandoz for out-licensing and commercialization of biosimilars.
Peer Comparison
| S.No. | Company Name | CMP (₹) | Market Cap (₹ Cr) | Div Yld (%) | NP Qtr (₹ Cr) | Qtr Profit Var (%) | Sales Qtr (₹ Cr) | Qtr Sales Var (%) | ROCE (%) | ROE (%) | Book Value (₹) | EPS TTM (₹) | TTMPE Ratio (₹) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Not Found Data | |||||||||||||
Coming Soon
Heatmap View
Premium Feature| Company | CMP (₹) | MCap (₹ Cr) | EPS TTM (₹) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Not Found Data | |||||||||||||
Financial Ratios
Premium Feature| Company Name | P/E (TTM) | EPS (₹) | D/E | NPM | GPM | ROE (%) | ROCE (%) | P/B | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Not Found Data | |||||||||||||
Coming Soon